Forecasting the Future Economic Burden of Current Adolescent Overweight: An Estimate of the Coronary Heart Disease Policy Model
- 1 December 2009
- journal article
- Published by American Public Health Association in American Journal of Public Health
- Vol. 99 (12) , 2230-2237
- https://doi.org/10.2105/ajph.2008.152595
Abstract
Objectives. We predicted the future economic burden attributable to high rates of current adolescent overweight. Methods. We constructed models to simulate the costs of excess obesity and associated diabetes and coronary heart disease (CHD) among adults aged 35–64 years in the US population in 2020 to 2050. Results. Current adolescent overweight is projected to result in 161 million life-years complicated by obesity, diabetes, or CHD and 1.5 million life-years lost. The cumulative excess attributable total costs are estimated at $254 billion: $208 billion because of lost productivity from earlier death or morbidity and $46 billion from direct medical costs. Currently available therapies for hypertension, hyperlipidemia, and diabetes, used according to guidelines, if applied in the future, would result in modest reductions in excess mortality (decreased to 1.1 million life-years lost) but increase total excess costs by another $7 billion (increased to $261 billion total). Conclusions. Current adolescent overweight will likely lead to large future economic and health burdens, especially lost productivity from premature death and disability. Application of currently available medical treatments will not greatly reduce these future burdens of increased adult obesity.Keywords
This publication has 54 references indexed in Scilit:
- Obesity and the lung: 3 {middle dot} Obesity, respiration and intensive careThorax, 2008
- Obesity and the lung: 5 {middle dot} Obesity and COPDThorax, 2008
- The Association of Diabetes With Job Absenteeism Costs Among Obese and Morbidly Obese WorkersJournal of Occupational and Environmental Medicine, 2008
- Adverse renal consequences of obesityAmerican Journal of Physiology-Renal Physiology, 2008
- Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Journal of General Internal Medicine, 2008
- The impact of obesity on the musculoskeletal systemInternational Journal of Obesity, 2007
- Prevalence of Overweight and Obesity in the United States, 1999-2004JAMA, 2006
- The Costs of Obesity among Full-Time EmployeesAmerican Journal of Health Promotion, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998